Research analysts at Zacks Research decreased their FY2024 EPS estimates for shares of Denali Therapeutics in a research report issued on Tuesday, January 28th. Zacks Research analyst A. Chakraborty ...

Denali Therapeutics (NASDAQ:DNLI – Free Report) had its target price trimmed by The Goldman Sachs Group from $45.00 to $40.00 in a research report sent to investors on Tuesday morning,Benzinga reports ...

In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against other biotech stocks with the biggest upside potential. While 2024 was a “challenging” year ...

Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, tividenofusp alfa (DNL310), for the treatment of individuals with ...

In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against other biotech stocks with the biggest upside potential. While 2024 was a “challenging ...

Denali Therapeutics Inc. (DNLI) stock price is 23.30 and Denali Therapeutics Inc. (DNLI) 10-day simple moving average is 23.08. Denali Therapeutics Inc. (DNLI) stock price is 23.30 and Denali ...

Denali Therapeutics (NASDAQ:DNLI) shares plunged 7% after its ALS treatment, DNL343, failed to meet its primary endpoint in a phase 2/3 study, according to topline results. The primary endpoint ...

In a report released today, Brendan Smith from TD Cowen maintained a Buy rating on Denali Therapeutics (DNLI – Research Report). The company’s shares closed yesterday at $19.59. Discover ...

In a report released today, Jessica Fye from J.P. Morgan maintained a Buy rating on Denali Therapeutics (DNLI – Research Report), with a price target of $24.00. The company’s shares closed ...